Heron Therapeutics, Inc.

As of February 23, 2017, Heron Therapeutics, Inc. is considered risky and overvalued due to negative valuation ratios and underperformance compared to peers and the S&P 500.

As of June 6, 2025, Heron Therapeutics, Inc. shows a mildly bullish trend, supported by bullish daily moving averages, despite mixed signals from weekly MACD and KST indicators.

As of February 23, 2017, Heron Therapeutics, Inc. is classified as risky and overvalued, with key financial ratios indicating distress, despite a year-to-date stock return of 37.91% compared to the S&P 500's 2.44%.

As of March 2022, the management team of Heron Therapeutics, Inc. includes Dr. Barry Quart as CEO and Chairman, and Ms. Kimberly Manhard as Executive VP of Drug Development. The Board of Directors features Mr. Craig Johnson as Lead Independent Director, along with Independent Directors Mr. Stephen Davis and Mr. Christian Waage.

Heron Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products for cancer and pain management. As of March 2025, it reported net sales of $39 million and a market cap of $297.5 million.

As of Jun 18, Heron Therapeutics, Inc. has a market capitalization of 297.50 million, with net sales of 148.51 million and a net profit of -7.79 million over the last four quarters. The company's shareholder's funds are -33.65 million, and total assets are 233.15 million.